Cerebain Biotech Competitors and Similar CompaniesClear all
Cerebain Biotech's competitors and similar companies include Emulate, XVIVO Perfusion and Eyenovia.
 XVIVO Perfusion XVIVO Perfusion is a medical technology company that develops machines and perfusion solutions. |  Eyenovia Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. | |||
Founding Date | Founding Date 2010 | Founding Date 2014 | Founding Date 1998 | Founding Date 2014 |
Type | Type Private | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations Costa Mesa, US HQ | Locations Boston, US HQ | Locations Mölndal, SE HQ Shanghai, CN Novegro Tregarezzo, IT Groningen, NL Lund, SE Mölndal, SE Aurora, US see more | Locations New York, US HQ |
Employees | Employees 2 | Employees 802% decrease | Employees 19320% increase | Employees 22100% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) 47.3 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr812.2m (FY, 2025) | Revenue (est.) $813.5k (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods kr208.5m (FY, 2025) | Cost of goods $303.3k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit kr605.4m (FY, 2025) | Gross profit $510.2k (FY, 2025) |
Net income | Net income ($4.9m) (FY, 2018) | Net income N/A | Net income kr25.2m (FY, 2025) | Net income ($45.3m) (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Emulate
HQ
Boston, US
Employees
80↓ 2% decrease
Emulate is a biotechnology company that specializes in organ-on-chips technology.
View companyXVIVO Perfusion
HQ
Mölndal, SE
Employees
193↑ 20% increase
XVIVO Perfusion is a medical technology company that develops machines and perfusion solutions.
View companyEyenovia
HQ
New York, US
Employees
22
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform.
View company